Loading...

CUE CUE BIOPHARMA INC Company Mergers 8-K Filing

C BP

C

CUE BIOPHARMA INC

(CUE)

2025 8-K

Financial Results Announced

Annual Meeting Notice

Management Change

Stock Offering Details

Executive Departure

Financial Results

Collaboration Agreement

Leadership Changes

Management Changes

Financial Statements

Public Offering

Collaboration Agreement

Financial Results

Board Appointment

Financial Results

Loan Agreement Update

Public Offering

Director Resignation

Nasdaq Deficiency Notice

Restructuring and Salary Cuts

Appointment of Michael J. F...

Financial Results Announcement

Resignation of Director

Annual Meeting Results

Appointment of Director

Appointment of Director

Retirement of Director

External Links:

Cue Biopharma, Inc. has entered into a collaboration with ImmunoScape Pte. Ltd. on November 6, 2025, allowing IMSCP to develop and commercialize certain oncology molecules from Cue's CUE-100 Series. Cue received $5 million upfront and will earn additional payments and royalties depending on sales and developments.

AI Assistant

CUE BIOPHARMA INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.